Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 15, 2025

SW480

RRID:CVCL_0546
Type: Cell Line

Proper Citation

(RRID:CVCL_0546)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0546

Proper Citation: (RRID:CVCL_0546)

Sex: Male

Defining Citation: PMID:286328, PMID:288927, PMID:327080, PMID:833871, PMID:924690, PMID:1000501, PMID:1389533, PMID:1778766, PMID:3349466, PMID:3518877, PMID:6582512, PMID:7104989, PMID:7459858, PMID:7651727, PMID:7824277, PMID:8422623, PMID:8895552, PMID:9000147, PMID:9000572, PMID:9290701, PMID:9294210, PMID:9715273, PMID:10612807, PMID:10674020, PMID:10737795, PMID:10773689, PMID:11113861, PMID:11226274, PMID:11414198, PMID:11416159, PMID:11526487, PMID:11668190, PMID:16418264, PMID:16854228, PMID:19927377, PMID:20215515, PMID:20570890, PMID:20606684, PMID:20831567, PMID:22460905, PMID:23272949, PMID:23932154, PMID:24042735, PMID:24755471, PMID:24840470, PMID:25485619, PMID:25841592, PMID:25877200, PMID:25926053, PMID:25944804, PMID:25984343, PMID:26537799, PMID:26589293, PMID:27987026, PMID:28196595, PMID:28683746, PMID:29101300, PMID:29131639, PMID:30894373, PMID:31059103, PMID:31068700, PMID:31978347, PMID:32172478

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: Protein expression by reverse-phase protein arrays., Omics: O-glycan profiling., Omics: Nuclear proteome analysis., Omics: N-glycan profiling., Omics: miRNA expression profiling., Omics: Hi-C chromosome conformation analysis., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep phosphoproteome analysis., Omics: Deep exome analysis., Population: Caucasian., From: Scott and White Clinic; Temple; USA., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AstraZeneca Colorectal cell line (AZCL)

panel.

Category: Cancer cell line

Name: SW480

Synonyms: SW-480, SW 480, SW480E

Cross References: BTO:BTO_0000038, BTO:BTO_0006552, CLO:CLO_0009195, CLO:CLO_0009217, CLO:CLO_0009218, EFO:EFO_0002083, MCCL:MCC:0000447, CLDB:cl4440, CLDB:cl4441, CLDB:cl4966, Abcam:ab271146, AddexBio:C0009001/43, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ATCC:CCL-228, BCRC:60249, BCRJ:0411, BioSample:SAMN01821602, BioSample:SAMN03481110, BioSample:SAMN05292431, BioSample:SAMN07709984, BioSample:SAMN07709985, BioSample:SAMN07709986, BioSample:SAMN07709987, BioSample:SAMN07709988, BioSample:SAMN07709989, BioSample:SAMN07709990, BioSample:SAMN10987646, cancercelllines:CVCL_0546, CCRID:1101HUM-PUMC000166, CCRID:3101HUMSCSP5033, CCRID:3101HUMTCHu172, CCRID:4201HUM-CCTCC00306, CCTCC:GDC0065, CCTCC:GDC0306, Cell_Model_Passport:SIDM00840, ChEMBL-Cells:CHEMBL3307758, ChEMBL-Targets:CHEMBL612544, CLS:300302, ColonAtlas:SW480, Cosmic:709847, Cosmic:711272, Cosmic:716169, Cosmic:720332, Cosmic:875293, Cosmic:876719, Cosmic:887240, Cosmic:889536, Cosmic:902791, Cosmic:905006, Cosmic:913892, Cosmic:948827, Cosmic:983732, Cosmic:985652, Cosmic:990302, Cosmic:995393, Cosmic:1043829, Cosmic:1057764, Cosmic:1066212, Cosmic:1071888, Cosmic:1122332, Cosmic:1132573, Cosmic:1132693, Cosmic:1154645, Cosmic:1176589, Cosmic:1184095, Cosmic:1184328, Cosmic:1187323, Cosmic:1223149, Cosmic:1310935, Cosmic:1332007, Cosmic:1374642, Cosmic:1466822, Cosmic:1479588, Cosmic:1482524, Cosmic:1486130, Cosmic:1524329, Cosmic:1552183, Cosmic:1571768, Cosmic:1609479, Cosmic:1676750, Cosmic:1708398, Cosmic:1803951, Cosmic:2036653, Cosmic:2145577, Cosmic:2156941, Cosmic:2267318, Cosmic:2301547, Cosmic:2302018, Cosmic:2433752, Cosmic:2646770, Cosmic:2651869, Cosmic:2664054, Cosmic:2668252, Cosmic:2727482, Cosmic:2760071, Cosmic:2787551, Cosmic:2800590, Cosmic:2823492, DepMap:ACH-000842, DSMZ:ACC-313, DSMZCellDive:ACC-313, ECACC:87092801, EGA:EGAS00001000610, ENCODE:ENCBS211HGL, ENCODE:ENCBS421AQW, FCS-free:180-2-342-3-16-3, GEO:GSM206552, GEO:GSM274771, GEO:GSM274772, GEO:GSM513930, GEO:GSM514312, GEO:GSM741258, GEO:GSM784022, GEO:GSM861349, GEO:GSM861350, GEO:GSM861351, GEO:GSM861352, GEO:GSM887674, GEO:GSM888766, GEO:GSM1006234, GEO:GSM1006235, GEO:GSM1346891, GEO:GSM1374928, GEO:GSM1374929, GEO:GSM1374930, GEO:GSM1448166, GEO:GSM1670508, GEO:GSM1862124, GEO:GSM1862125, GEO:GSM1862126, GEO:GSM2299788, GEO:GSM2550016, GEO:GSM3258549, GEO:GSM3399745, GEO:GSM3399746, GEO:GSM3591767, IARC_TP53:96, IARC_TP53:23572, ICLC:HTL99017, IGRhCellID:SW480, KCB:KCB 200848YJ, KCLB:10228, LiGeA:CCLE_461, Lonza:816, MetaboLights:MTBLS227, NCBI_Iran:C506, PharmacoDB:SW480_1539_2019, PRIDE:PXD000089, PRIDE:PXD000230, PRIDE:PXD001550, PRIDE:PXD002793, PRIDE:PXD003708, PRIDE:PXD005354, PRIDE:PXD005355, PRIDE:PXD006662, PRIDE:PXD019478, PRIDE:PXD019479,

RCB:RCB1959, Progenetix:CVCL_0546, PubChem_Cell_line:CVCL_0546, SKY/M-FISH/CGH:2839, SKY/M-FISH/CGH:3982, TKG:TKG 0505, TOKU-E:3233, Ubigene:YC-C057, Wikidata:Q28472974

ID: CVCL_0546

Record Creation Time: 20250131T202735+0000

Record Last Update: 20250131T204714+0000

Ratings and Alerts

No rating or validation information has been found for SW480.

Warning: Discontinued: RCB; RCB1959
Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: Protein expression by reverse-phase protein arrays., Omics: O-glycan profiling., Omics: Nuclear proteome analysis., Omics: N-glycan profiling., Omics: miRNA expression profiling., Omics: Hi-C chromosome conformation analysis., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep phosphoproteome analysis., Omics: Deep exome analysis., Population: Caucasian., From: Scott and White Clinic; Temple; USA., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AstraZeneca Colorectal cell line (AZCL) panel. Warning: Discontinued: TKG; TKG 0505
Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: Protein expression by reverse-phase protein arrays., Omics: O-glycan profiling., Omics: Nuclear proteome analysis., Omics: N-glycan profiling., Omics: miRNA expression profiling., Omics: Hi-C chromosome conformation analysis., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep phosphoproteome analysis., Omics: Deep exome analysis., Population: Caucasian., From: Scott and White Clinic; Temple; USA., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AstraZeneca Colorectal cell line (AZCL) panel.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 3966 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Champagne J, et al. (2025) Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation. Immunity, 58(1), 247.

Yong Y, et al. (2025) AMIGO2 characterizes cancer-associated fibroblasts in metastatic colon cancer and induces the release of paracrine active tumorigenic secretomes. The Journal of pathology, 265(1), 14.

Jothimani G, et al. (2025) Unraveling the mechanism of microRNA-134 in colon cancer progression: Targeting KRAS and PIK3CA for cell cycle control and histone deacetylase regulation. Experimental cell research, 444(2), 114385.

Tian X, et al. (2025) Histone-acetyl epigenome regulates TGF-? pathway-associated chemoresistance in colorectal cancer. Translational oncology, 51, 102166.

Sun YM, et al. (2024) lncRNAs maintain the functional phase state of nucleolar prion-like protein to facilitate rRNA processing. Molecular cell, 84(24), 4878.

Ibáñez-Molero S, et al. (2024) Phosphoprotein dynamics of interacting T cells and tumor cells by HySic. Cell reports, 43(1), 113598.

Li HM, et al. (2024) PHGDH knockdown increases sensitivity to SR1, an aryl hydrocarbon receptor antagonist, in colorectal cancer by activating the autophagy pathway. The FEBS journal.

Singh H, et al. (2024) RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(8), 1669.

Slaninová V, et al. (2024) The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells. BMC cancer, 24(1), 587.

Teng HW, et al. (2024) CT45A1-mediated MLC2 (MYL9) phosphorylation promotes natural killer cell resistance and outer cell fate in a cell-in-cell structure, potentiating the progression of microsatellite instability-high colorectal cancer. Molecular oncology.

Martins F, et al. (2024) KRAS silencing impacts chromatin organization and transcriptional activity in colorectal cancer cells. Research square.

De La Cruz-Sigüenza DA, et al. (2024) The non-vesicle cell-free DNA (cfDNA) induces cell transformation associated with horizontal DNA transfer. Molecular biology reports, 51(1), 174.

Zhang C, et al. (2024) Non-alcoholic fatty liver disease promotes liver metastasis of

colorectal cancer via fatty acid synthase dependent EGFR palmitoylation. Cell death discovery, 10(1), 41.

Kang ZR, et al. (2024) Deficiency of BCAT2-mediated branched-chain amino acid catabolism promotes colorectal cancer development. Biochimica et biophysica acta. Molecular basis of disease, 1870(2), 166941.

Lee S, et al. (2024) B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies. EBioMedicine, 110, 105459.

Schmidt O, et al. (2024) AXIN2 promotes degradation of AXIN1 through tankyrase in colorectal cancer cells. The FEBS journal.

Wu S, et al. (2024) Targeting high circDNA2v levels in colorectal cancer induces cellular senescence and elicits an anti-tumor secretome. Cell reports, 43(4), 114111.

Li L, et al. (2024) Comprehensive Proteogenomic Profiling Reveals the Molecular Characteristics of Colorectal Cancer at Distinct Stages of Progression. Cancer research, 84(17), 2888.

Cheng L, et al. (2024) Jianpi Jiedu Recipe Inhibits Proliferation through Reactive Oxygen Species-Induced Incomplete Autophagy and Reduces PD-L1 Expression in Colon Cancer. Integrative cancer therapies, 23, 15347354241268064.

Mondal P, et al. (2024) Disrupting the interaction between a p53 gain-of-function mutant and the transcriptional co-activator PC4 reverses drug resistance in cancer cells. FEBS letters, 598(12), 1532.